UBS AM
OSIR

UBS AM’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

UBS AM’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,400
Closed -$173K – 2633
2013
Q3 		$173K Buy
+10,400
New +$154K ﹤0.01% 2373

Other funds holding OSIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

UBS AM's OSIR Position: Q4 2013 in Review

UBS AM sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q4 2013, closing a stake of 10,400 shares — an estimated $173K sold.

UBS AM first reported a position in OSIR in Q3 2013 and held it in 1 quarter. The position peaked at $173K in Q3 2013. 67 funds tracked by Wall St. Rank hold OSIR as of Q4 2013.

  • UBS AM reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • UBS AM sold 10,400 Osiris Therapeutics, Inc. Common Stock shares in Q4 2013, an estimated $173K.
  • UBS AM first reported a position in Osiris Therapeutics, Inc. Common Stock in Q3 2013 and held it in 1 quarter.
  • UBS AM's Osiris Therapeutics, Inc. Common Stock position peaked at $173K in Q3 2013.
  • 67 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q4 2013.

Based on UBS AM's 13F filing for Q4 2013, filed 31 Jan 2014.